Clearstead Advisors’s Aura Biosciences AURA Stock Holding History

Clearstead Advisors’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-23	Closed	-$165	–	3538
2026 Q2	$165	Buy	+23	New	+$165	﹤0.01%	3250

Other funds holding AURA

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return

Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Levin Capital Strategies New York $1.42B AUM 19.05% 1-Year Est. Return

Clearstead Advisors's AURA Position: Q3 2026 in Review

Clearstead Advisors sold out of Aura Biosciences (AURA) in Q3 2026, closing a stake of 23 shares — an estimated $165 sold.

Clearstead Advisors first reported a position in AURA in Q2 2026 and held it in 1 quarter. The position peaked at $165 in Q2 2026. 98 funds tracked by Wall St. Rank hold AURA as of Q3 2026.

Clearstead Advisors reported no remaining Aura Biosciences position as of Q3 2026 after selling out during the quarter.
Clearstead Advisors sold 23 Aura Biosciences shares in Q3 2026, an estimated $165.
Clearstead Advisors first reported a position in Aura Biosciences in Q2 2026 and held it in 1 quarter.
Clearstead Advisors's Aura Biosciences position peaked at $165 in Q2 2026.
98 funds tracked by Wall St. Rank held Aura Biosciences as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.